US Patent Issued to Tokyo Women's Medical University, Hiroshima University, Chugai Seiyaku on March 24 for "Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination" (Japanese Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,918, issued on March 24, was assigned to Tokyo Women's Medical University (Tokyo), Hiroshima University (Hiroshima, Japan) and Chugai Seiyaku K.K. (Tokyo).

"Therapeutic agent for urological cancer which is characterized by being administered with IL-6 inhibitor and CCR2 inhibitor in combination" was invented by Hiroaki Honda (Tokyo) and Kohei Kobatake (Hiroshima, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity a...